Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix (OCUL) had its "buy" rating reaffirmed by HC Wainwright. They now have a $21.00 price target on the stock.
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April
Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds [Yahoo! Finance]